Published in Gene Ther on August 01, 2001
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (2008) 3.30
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther (2011) 2.91
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther (2011) 1.90
Treatment of human disease by adeno-associated viral gene transfer. Hum Genet (2006) 1.84
AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther (2005) 1.80
Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. Hum Gene Ther Methods (2012) 1.79
Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol (2002) 1.77
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther (2013) 1.73
Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther (2009) 1.71
Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One (2013) 1.70
Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther (2009) 1.64
Adeno-associated virus: from defective virus to effective vector. Virol J (2005) 1.60
High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol (2006) 1.55
Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther (2009) 1.36
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest (2007) 1.34
The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther (2012) 1.30
Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia. J Virol (2003) 1.28
Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. Hum Gene Ther (2015) 1.27
AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther (2010) 1.27
Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther (2011) 1.21
Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol (2005) 1.21
Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. Virology (2006) 1.21
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res (2013) 1.20
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther (2008) 1.18
Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol (2004) 1.17
Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther (2012) 1.16
The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J (2007) 1.16
Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci (2009) 1.16
Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol (2005) 1.15
Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci (2009) 1.14
Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol (2011) 1.11
Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain (2006) 1.11
Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A (2009) 1.11
Self-complementary AAV2.5-BMP2-coated femoral allografts mediated superior bone healing versus live autografts in mice with equivalent biomechanics to unfractured femur. Mol Ther (2011) 1.10
Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet (2012) 1.10
The gene therapy journey for hemophilia: are we there yet? Blood (2012) 1.10
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther (2009) 1.09
Rapid, long-term labeling of cells in the developing and adult rodent visual cortex using double-stranded adeno-associated viral vectors. Dev Neurobiol (2009) 1.07
Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther (2005) 1.05
Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol (2012) 1.04
AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One (2014) 1.04
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Adeno-associated virus: a key to the human genome? Future Virol (2010) 1.03
Gene therapy for bone healing. Expert Rev Mol Med (2010) 1.02
Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. Hum Gene Ther (2011) 1.01
Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. Hum Mol Genet (2011) 1.01
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog Neurobiol (2011) 1.00
Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol (2014) 1.00
Recombinant adeno-associated viral vectors are deficient in provoking a DNA damage response. J Virol (2008) 1.00
Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models. Hum Gene Ther (2010) 0.99
Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv (2010) 0.98
Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics (2014) 0.98
Current status of gene therapy for inherited lung diseases. Annu Rev Physiol (2002) 0.98
Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther (2010) 0.98
Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther (2005) 0.97
A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol (2013) 0.97
Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther (2009) 0.97
Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside. J Ophthalmol (2010) 0.96
Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther (2010) 0.95
Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med (2009) 0.95
Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes. J Virol (2010) 0.95
Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods (2012) 0.95
Gene therapy: progress and predictions. Proc Biol Sci (2015) 0.94
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues. Mol Ther (2011) 0.94
Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. Mol Ther (2011) 0.94
Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol (2014) 0.94
Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector. Mol Ther (2015) 0.93
Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus. Genet Vaccines Ther (2007) 0.93
Neuroanatomy goes viral! Front Neuroanat (2015) 0.93
Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus. Arch Ophthalmol (2010) 0.93
Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol Ther (2013) 0.92
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol (2015) 0.91
CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol Ther (2013) 0.91
Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. PLoS One (2011) 0.90
A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol (2015) 0.90
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther (2012) 0.90
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther (2012) 0.89
Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model. Hum Gene Ther (2011) 0.89
scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther (2012) 0.89
Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. J Virol (2014) 0.89
Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med (2011) 0.89
Clinical applications involving CNS gene transfer. Adv Genet (2014) 0.89
Methods for gene transfer to the central nervous system. Adv Genet (2014) 0.88
In vivo gene knockdown in rat dorsal root ganglia mediated by self-complementary adeno-associated virus serotype 5 following intrathecal delivery. PLoS One (2012) 0.88
Insight into the mechanism of inhibition of adeno-associated virus by the Mre11/Rad50/Nbs1 complex. J Virol (2014) 0.87
Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol (2011) 0.87
A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther (2008) 0.87
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. J Biomed Sci (2009) 0.87
VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis (2010) 0.85
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther (1999) 7.96
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet (1994) 5.49
Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell (1983) 5.27
AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5.26
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol (1987) 4.57
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther (2000) 3.32
In vitro resolution of covalently joined AAV chromosome ends. Cell (1990) 3.24
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol (1993) 2.69
Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol (1997) 2.32
Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol (1997) 2.19
Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. J Virol (1987) 2.09
Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 2.06
Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells. J Virol (1992) 1.86
Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A (1992) 1.82
Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology (1999) 1.76
Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood (1994) 1.75
Immune responses to AAV in a phase I study for Canavan disease. J Gene Med (2006) 1.74
Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol (1997) 1.73
The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med (2001) 1.69
Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther (2001) 1.65
Rapid purification of covalently closed circular DNAs of bacterial plasmids and animal tumor viruses. Anal Biochem (1980) 1.60
A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol (1997) 1.57
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther (1998) 1.52
Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol (1999) 1.51
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther (2011) 1.47
AAV vectors: is clinical success on the horizon? Gene Ther (2000) 1.47
Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today (2000) 1.45
Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest (1994) 1.39
Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol (2000) 1.37
Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol (2000) 1.32
Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci U S A (1994) 1.28
Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther (2003) 1.25
Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med (2000) 1.25
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther (2011) 1.24
Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci U S A (2001) 1.21
New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med (1997) 1.21
Building a better vector: the manipulation of AAV virions. Virology (2000) 1.19
Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J Virol (1998) 1.17
Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proc Natl Acad Sci U S A (1989) 1.17
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther (1998) 1.16
Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg (1996) 1.16
Gene therapy for human hemoglobinopathies. Proc Soc Exp Biol Med (1993) 1.15
The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther (2000) 1.14
Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Ther (2006) 1.12
Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther (1998) 1.09
Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther (2012) 1.09
Gene therapy: targeting the myocardium. Heart (2008) 1.06
Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther (2007) 1.05
Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther (2005) 1.05
Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant (2001) 1.04
Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost (2009) 0.99
NIDDK Workshop on AAV Vectors: Gene Transfer into Quiescent Cells. Hum Gene Ther (1996) 0.98
Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci U S A (1996) 0.98
Kinetics of recombinant adeno-associated virus-mediated gene transfer. J Virol (2000) 0.98
Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J Immunother (1991) (1992) 0.98
Delivery of the Cu/Zn-superoxide dismutase gene with adenovirus reduces early alcohol-induced liver injury in rats. Gastroenterology (2001) 0.98
Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther (2005) 0.97
Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther (2009) 0.97
Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy. Nat Med (1998) 0.97
Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res (1997) 0.96
Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther (2010) 0.95
Heart failure: a silver bullet to treat heart failure. Gene Ther (2006) 0.95
Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF. J Comp Neurol (2009) 0.92
Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med (1999) 0.91
Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther (2011) 0.91
Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther (2008) 0.90
The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. Gene Ther (2011) 0.90
AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol Biotechnol (1995) 0.89
AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp Neurol (2008) 0.88
Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy. Gene Ther (2011) 0.87
Cu/Zn-superoxide dismutase gene attenuates ischemia-reperfusion injury in the rat kidney. J Am Soc Nephrol (2001) 0.87
A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther (2008) 0.87
Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther (2001) 0.86
Charge-to-alanine mutagenesis of the adeno-associated virus type 2 Rep78/68 proteins yields temperature-sensitive and magnesium-dependent variants. J Virol (1999) 0.86
Site-specific targeting of DNA plasmids to chromosome 19 using AAV cis and trans sequences. Methods Mol Biol (2000) 0.85
Familial deficiency of vitamin K-dependent clotting factors. Haemophilia (2008) 0.85
Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: a new perspective for in-stent restenosis gene therapy. Gene Ther (2013) 0.83
Three-dimensional multipotent progenitor cell aggregates for expansion, osteogenic differentiation and 'in vivo' tracing with AAV vector serotype 6. Gene Ther (2012) 0.83
Delivery of Cu/Zn-superoxide dismutase genes with a viral vector minimizes liver injury and improves survival after liver transplantation in the rat. Transplantation (2000) 0.80
Expanding the AAV package. Nat Biotechnol (2000) 0.80
Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia (2013) 0.80
Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NFkappaB-dependent mechanisms. Hepatology (2000) 0.80
IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost (2013) 0.80
The genetics of adeno-associated virus. Adv Exp Med Biol (1984) 0.79
Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia (2012) 0.79
Methods for adeno-associated virus-mediated gene transfer into muscle. Methods Mol Biol (2001) 0.79